Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (20)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Ducloux, D.
Right arrow Articles by Chalopin, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ducloux, D.
Right arrow Articles by Chalopin, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrology Dialysis Transplantation, Vol 12, Issue 11 2389-2392, Copyright © 1997 by Oxford University Press

ORIGINAL ARTICLES

Colchicine myopathy in renal transplant recipients on cyclosporin

D Ducloux, V Schuller, C Bresson-Vautrin and J Chalopin
Department of Nephrology and Renal Transplantation, Hopital saint Jacques, Besancon, France; Corresponding author

Few data are available about the muscle status in renal transplant recipients. Moreover, the list of myotoxic drugs is growing longer and some of them are likely to be prescribed in renal transplant patients. These conditions may act as confounding factors in case reports of both cyclosporin and colchicine myopathies. Moreover no study has evaluated the frequency of myopathy in patients on both colchicine and cyclosporin. We conducted a retrospective study including all renal transplant recipients followed in our unit in whom colchicine was prescribed since January 1994. Clinical and biological data of patients on both colchicine and cyclosporin were analysed. Secondly case subjects were compared with matched controls not receiving colchicine but cyclosporin. Ten patients received colchicine in association with cyclosporin. Five patients (50%) experienced muscular symptoms and when performed, muscular histology showed vacuolar myopathy. All five patients improved after colchicine withdrawal. Cases with and without muscular symptoms did not differ in age, transplant duration, and serum creatinine level. Mean duration of colchicine therapy was 12.2±4.4 months in cases with muscular symptoms and 6.8±5.6 months in cases without muscular symptoms (P <0.05). No control complained of either muscular pain nor weakness (P <0.0005). Only one patient (3.3%) had elevated serum creatine phosphokinase concentration (P <0.0005). We conclude that myopathy is very frequent in patient on both colchicine and cyclosporin. Muscular symptoms improve in all patients after colchicine withdrawal. Key words: biological data; colchicine; cyclosporin; drug effects; muscle; myopathy
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 NEJMHome page
R. A. Terkeltaub
Gout
N. Engl. J. Med., October 23, 2003; 349(17): 1647 - 1655.
[Full Text] [PDF]

Home page
 NeurologyHome page
A. Shinde, S. Nakano, M. Abe, N. Kohara, I. Akiguchi, and H. Shibasaki
Accumulation of microtubule-based motor protein in a patient with colchicine myopathy
Neurology, November 14, 2000; 55(9): 1414 - 1415.
[Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.